Lilly’s new center in Boston will focus on genetic medicine research and provide lab space for startups. Elsewhere, two biotechs cut jobs and two others advanced psychedelic medicines.
Read more about this post on BioPharmaDive
Trending
- Druckenmiller’s Duquesne Office Expands Portfolio with Broadcom and Caris Life Sciences Investments
- UberDoc Health Technologies Unveils New Leadership Team
- NMPA 2025: A New Era of Approvals in China
- Exploring the Future of Research, Cell Therapy, and Reagent Demand
- Dengue Cases Plummet 66% in Early 2026 as Home Breeding Sites Identified
- Bicara Stock Soars 50%, Boosting Biotech Investor’s Portfolio by 29%
- Navigating the Future of Consumer-Centric Therapeutics
- Bridging the Gap: AI’s Role in Digital Health Equity
